

Product Data Sheet

Rapamycin (GMP)

Cat. No.: HY-10219G

CAS No.: 53123-88-9

Molecular Formula: $C_{51}H_{79}NO_{13}$ Molecular Weight: 914

Molecular Weight: 914
Target: mTOR

Pathway: PI3K/Akt/mTOR

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin is a potent and specific mTOR inhibitor $^{[1][2][3]}$.
In Vitro	Rapamycin (GMP) (1 nM; 2-3 weeks) induces in vitro differentiation of human embryonic stem cell (hESCs) into mineralized osteoblasts ^[1] . Rapamycin (GMP) (1 nM; 2-3 weeks) enhances the osteoblastic differentiation of human embryoid bodies (hEBs) ^[1] . Rapamycin (GMP) (20 nM; 4 h) serum-dependently promotes vascular smooth muscle cells (VSMCs) differentiation ^[2] . Rapamycin (GMP) induces osteoblastic differentiation in rat osteoblast-like osteosarcoma cells ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nature. 2021 Jun;594(7862):271-276.
- Nature. 2018 Jun;558(7711):540-546.
- Nature. 2016 Dec 1;540(7631):119-123.
- Cell. 2023 Jun 22;186(13):2802-2822.e22.
- Cancer Cell. 2021 Mar 8;39(3):380-393.e8.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lee KW, et al. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev. 2010 Apr;19(4):557-68.

[2]. Martin KA, et al. Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling. J Biol Chem. 2007 Dec 7;282(49):36112-20.



Page 2 of 2 www.MedChemExpress.com